Holen Sie sich die Stockscreener-App
4.935
2.66%
-0.135
Vyome Holdings Inc Aktie (HIND) Neueste Nachrichten
Will Vyome's Topical Gel Be The First FDA-Approved Treatment For Cancer Wounds? - RTTNews
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics By Investing.com - Investing.com South Africa
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics - Investing.com Nigeria
Vyome Holdings acquires MIT AI spinout Oculo Health - MarketScreener
Vyome shares surge after encouraging preclinical data for eye treatment - MSN
BC-Most Active Stocks - upstatetoday.com
Why Is BBAI Stock Falling Today? - Stocktwits
HIND Stock Rallies 70% Pre-Market Today Find Out Why - Menafn
HIND Stock: Growth or Bubble? - StocksToTrade
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Asianet Newsable
Vyome Holdings (HIND) Skyrockets Over 50% on Breakthrough Uveitis Treatment News - RagingBull
Vyome stock soars after positive preclinical results for eye drug - Investing.com India
Vyome stock soars after positive preclinical results for eye drug By Investing.com - Investing.com Nigeria
Morning Market Movers: SPRC, HIND, SQFT, FGNX See Big Swings - RTTNews
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity - Business Wire
Vertiv’s Stock Surge: Will it Last? - StocksToTrade
Vyome Holdings Appoints Dr. Richard Fahrner as CTO and Dr. Tamara Agajanov, MD, as SVP – Clinical Development - citybiz
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Nigeria
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com India
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com Canada
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):